CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LRCH3 (ImmuneEditome ID:84859)

1. Gene summary of enriched editing regions for LRCH3

check button Gene summary
Gene informationGene symbol

LRCH3

Gene ID

84859

GeneSynonyms-
GeneCytomap

3q29

GeneTypeprotein-coding
GeneDescriptionDISP complex protein LRCH3|leucine-rich repeat and calponin homology domain-containing protein 3|leucine-rich repeats and calponin homology (CH) domain containing 3
GeneModificationdate20230329
UniprotIDQ96II8;F8WFB5;H7C0J8;E9PD99;H7C1G3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:197817913-197819004:+ENST00000334859.7ENSG00000186001.11LRCH3intronicAluY,MIRb,AluSxchr3:197817913-197819004:+.alignment
chr3:197817913-197819004:+ENST00000414675.5ENSG00000186001.11LRCH3intronicAluY,MIRb,AluSxchr3:197817913-197819004:+.alignment
chr3:197817913-197819004:+ENST00000425562.5ENSG00000186001.11LRCH3intronicAluY,MIRb,AluSxchr3:197817913-197819004:+.alignment
chr3:197817913-197819004:+ENST00000438796.5ENSG00000186001.11LRCH3intronicAluY,MIRb,AluSxchr3:197817913-197819004:+.alignment
chr3:197817913-197819004:+ENST00000441090.5ENSG00000186001.11LRCH3intronicAluY,MIRb,AluSxchr3:197817913-197819004:+.alignment
chr3:197817913-197819004:+ENST00000443727.1ENSG00000186001.11LRCH3intronicAluY,MIRb,AluSxchr3:197817913-197819004:+.alignment
chr3:197841887-197843040:+ENST00000494069.1ENSG00000186001.11LRCH3ncRNA_intronicL2a,MamRep605,AluSx,AluJbchr3:197841887-197843040:+.alignment
chr3:197844710-197845339:+ENST00000494069.1ENSG00000186001.11LRCH3ncRNA_intronicAluSz6,AluSc,L2achr3:197844710-197845339:+.alignment
chr3:197863386-197865289:+ENST00000461674.4ENSG00000186001.11LRCH3ncRNA_intronicAluSp,AluSc,(T)n,AluJr,AluJochr3:197863386-197865289:+.alignment
chr3:197863386-197865289:+ENST00000471667.4ENSG00000186001.11LRCH3ncRNA_intronicAluSp,AluSc,(T)n,AluJr,AluJochr3:197863386-197865289:+.alignment
chr3:197863386-197865289:+ENST00000473177.1ENSG00000186001.11LRCH3ncRNA_intronicAluSp,AluSc,(T)n,AluJr,AluJochr3:197863386-197865289:+.alignment
chr3:197863386-197865289:+ENST00000481048.4ENSG00000186001.11LRCH3ncRNA_intronicAluSp,AluSc,(T)n,AluJr,AluJochr3:197863386-197865289:+.alignment
chr3:197863386-197865289:+ENST00000483442.4ENSG00000186001.11LRCH3ncRNA_intronicAluSp,AluSc,(T)n,AluJr,AluJochr3:197863386-197865289:+.alignment
chr3:197872187-197875463:+ENST00000466054.1ENSG00000186001.11LRCH3ncRNA_intronicMER58A,L2c,MER1A,AluSp,AluJr,AluSc,AluJb,AluJo,AluSx,L1ME2z,LTR16A1,FLAM_Achr3:197872187-197875463:+.alignment
chr3:197872187-197875463:+ENST00000471667.4ENSG00000186001.11LRCH3ncRNA_intronicMER58A,L2c,MER1A,AluSp,AluJr,AluSc,AluJb,AluJo,AluSx,L1ME2z,LTR16A1,FLAM_Achr3:197872187-197875463:+.alignment
chr3:197872187-197875463:+ENST00000473177.1ENSG00000186001.11LRCH3ncRNA_intronicMER58A,L2c,MER1A,AluSp,AluJr,AluSc,AluJb,AluJo,AluSx,L1ME2z,LTR16A1,FLAM_Achr3:197872187-197875463:+.alignment
chr3:197872187-197875463:+ENST00000483442.4ENSG00000186001.11LRCH3ncRNA_intronicMER58A,L2c,MER1A,AluSp,AluJr,AluSc,AluJb,AluJo,AluSx,L1ME2z,LTR16A1,FLAM_Achr3:197872187-197875463:+.alignment
chr3:197884170-197886782:+ENST00000425562.5ENSG00000186001.11LRCH3UTR3AluSg4,AluJb,FLAM_C,Alu,AluSp,AluSx1chr3:197884170-197886782:+.alignment
chr3:197884170-197886782:+ENST00000438796.5ENSG00000186001.11LRCH3UTR3AluSg4,AluJb,FLAM_C,Alu,AluSp,AluSx1chr3:197884170-197886782:+.alignment


Top

2. Tumor-specific enriched editing regions for LRCH3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:197884170-197886782:+BRCAEER1.5697e-05image
ENSG00000186001.11,LRCH3BRCAEAG4.7768e-06image
chr3:197884170-197886782:+COADEER7.2893e-06image
ENSG00000186001.11,LRCH3COADEAG1.5706e-06image
ENSG00000186001.11,LRCH3KICHEAG6.4903e-04image
chr3:197884170-197886782:+KIRCEER2.3003e-02image
ENSG00000186001.11,LRCH3KIRCEAG1.4771e-02image
chr3:197884170-197886782:+LIHCEER1.5046e-02image
ENSG00000186001.11,LRCH3LIHCEAG9.4343e-03image
chr3:197884170-197886782:+LUSCEER2.0637e-14image
ENSG00000186001.11,LRCH3LUSCEAG2.1433e-14image
chr3:197884170-197886782:+THCAEER5.0819e-10image
ENSG00000186001.11,LRCH3THCAEAG1.9539e-09image
chr3:197884170-197886782:+UCECEER4.8296e-03image
ENSG00000186001.11,LRCH3UCECEAG7.1064e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000186001.11,LRCH3CESCCliEAG2.9980e-021.0575e-020.1484image
chr3:197884170-197886782:+KIRPCliEER4.6810e-022.8517e-020.1561image
ENSG00000186001.11,LRCH3SKCMPathEAG4.8291e-029.2877e-030.1280image
chr3:197863386-197865289:+STADPathEER1.9024e-024.8431e-03-0.3331image
chr3:197884170-197886782:+THCAPathEER3.9480e-023.1391e-020.0963image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr3:197884170-197886782:+GBMEER1.0585e-025.9118e-038.9631e-04image
ENSG00000186001.11,LRCH3GBMEAG7.9273e-045.1009e-037.1311e-04image
chr3:197884170-197886782:+OVEER4.4525e-022.2839e-023.5073e+01image
ENSG00000186001.11,LRCH3OVEAG4.7572e-022.9600e-023.2294e+01image

Top

3. Enriched editing regions and immune related genes for LRCH3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:197884170-197886782:+UVMEERENSG00000140320,BAHD1-0.48611.7644e-032.9590e-04-0.4015imageNNNAMacrophages_M0GSVA_HALLMARK_UV_RESPONSE_DN
chr3:197884170-197886782:+READEERENSG00000143442,POGZ-0.47142.8895e-022.7696e-05-0.4200imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_ADIPOGENESIS
chr3:197884170-197886782:+UVMEERENSG00000140320,BAHD1-0.48611.7644e-032.9590e-04-0.4015imageNNNAMacrophages_M0GSVA_HALLMARK_UV_RESPONSE_DN
chr3:197884170-197886782:+READEERENSG00000143442,POGZ-0.47142.8895e-022.7696e-05-0.4200imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_ADIPOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for LRCH3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000042753.7chr1946838739:46838799:46839464:46839594:46845998:46846142:46850763:468507660.25881.0941e-025.9809e-140.4434imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184AP2S1EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000042753.7chr1946838739:46838799:46839464:46839594:46846043:46846142:46850763:468507660.25881.0941e-025.9809e-140.4434imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184AP2S1EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000126261.8chr1934451980:34452147:34454259:34454353:34460469:34460566:34464025:34464119-0.24382.2020e-027.5013e-13-0.4254imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAMast_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000110700.2chr1117075096:17075197:17075453:17075491:17075588:17075623:17077167:170772460.25391.2622e-021.1175e-180.5108imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000110700.2chr1117075096:17075197:17075453:17075572:17075588:17075623:17077167:170772460.25401.2693e-021.5956e-180.5088imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000185043.6chr1590231356:90231507:90232218:90232427:90232978:90233703:90233834:902340470.32222.4936e-041.2706e-230.5681imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184CIB1Dendritic_cells_activatedGSVA_HALLMARK_P53_PATHWAY
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000110700.2chr1117075096:17075197:17075453:17075546:17075588:17075623:17077167:170772460.25351.2868e-021.1765e-180.5105imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000186001.11,LRCH3
COADEAGIRENSG00000178623.7chr2240617089:240618496:240618887:2406190310.23333.0836e-024.3010e-140.4488imageNADAR;AUH;BCCIP;BUD13;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28;MBNL2;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;VIM;YWHAGNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
ENSG00000186001.11,LRCH3
COADEAGIRENSG00000173120.10chr1167217542:67217884:67219287:672194030.20263.7620e-023.5667e-110.4074imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000186001.11,LRCH3
COADEAGMEXENSG00000168894.5chr285595816:85595849:85596518:85596645:85596906:85596931:85597103:85597178-0.24132.4610e-028.5471e-13-0.4244imageNAUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for LRCH3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:197884170-197886782:+ACCEEREosinophils2.1379e-030.3561image
ENSG00000186001.11,LRCH3ACCEAGEosinophils1.5896e-020.2814image
chr3:197884170-197886782:+BLCAEERT_cells_CD4_memory_resting1.2854e-03-0.1600image
ENSG00000186001.11,LRCH3BLCAEAGT_cells_CD4_memory_resting2.9840e-03-0.1478image
chr3:197884170-197886782:+BRCAEERT_cells_CD4_memory_activated7.1213e-060.1364image
ENSG00000186001.11,LRCH3BRCAEAGB_cells_naive2.0466e-06-0.1437image
chr3:197884170-197886782:+CESCEERNK_cells_activated1.7512e-02-0.1369image
ENSG00000186001.11,LRCH3CESCEAGNK_cells_activated1.3147e-02-0.1428image
chr3:197884170-197886782:+COADEERB_cells_naive3.0568e-02-0.1355image
ENSG00000186001.11,LRCH3COADEAGDendritic_cells_activated8.5465e-050.2412image
chr3:197884170-197886782:+DLBCEERT_cells_regulatory_(Tregs)2.5303e-02-0.3227image
ENSG00000186001.11,LRCH3DLBCEAGT_cells_regulatory_(Tregs)2.0040e-02-0.3348image
chr3:197863386-197865289:+ESCAEERT_cells_CD4_naive2.3393e-020.3202image
chr3:197872187-197875463:+ESCAEERDendritic_cells_activated1.7808e-030.3057image
chr3:197884170-197886782:+ESCAEERT_cells_CD4_memory_resting3.0639e-03-0.2320image
ENSG00000186001.11,LRCH3ESCAEAGT_cells_CD4_memory_resting2.0019e-02-0.1832image
chr3:197884170-197886782:+HNSCEERT_cells_regulatory_(Tregs)1.1106e-02-0.1142image
ENSG00000186001.11,LRCH3HNSCEAGT_cells_regulatory_(Tregs)6.8960e-03-0.1214image
chr3:197884170-197886782:+KIRCEERT_cells_gamma_delta3.4054e-050.2120image
ENSG00000186001.11,LRCH3KIRCEAGT_cells_gamma_delta2.4798e-040.1877image
chr3:197884170-197886782:+KIRPEERMacrophages_M11.6675e-030.1861image
ENSG00000186001.11,LRCH3KIRPEAGMacrophages_M12.6480e-030.1780image
chr3:197863386-197865289:+LAMLEERMast_cells_resting3.0948e-020.2181image
chr3:197884170-197886782:+LAMLEERT_cells_CD4_memory_resting4.2499e-02-0.2003image
chr3:197884170-197886782:+LGGEERT_cells_CD4_naive6.4373e-040.1483image
ENSG00000186001.11,LRCH3LGGEAGT_cells_CD4_naive3.3628e-040.1556image
chr3:197884170-197886782:+LIHCEERDendritic_cells_resting4.0746e-03-0.1534image
ENSG00000186001.11,LRCH3LIHCEAGDendritic_cells_resting1.0971e-03-0.1735image
chr3:197884170-197886782:+LUADEERPlasma_cells9.1587e-03-0.1187image
ENSG00000186001.11,LRCH3LUADEAGPlasma_cells8.4731e-03-0.1194image
chr3:197872187-197875463:+LUSCEERMonocytes1.0264e-020.5241image
chr3:197884170-197886782:+LUSCEERT_cells_gamma_delta2.9224e-030.1335image
ENSG00000186001.11,LRCH3LUSCEAGT_cells_gamma_delta2.5041e-030.1356image
chr3:197884170-197886782:+MESOEERNK_cells_resting2.4665e-020.2480image
ENSG00000186001.11,LRCH3MESOEAGNK_cells_resting2.9567e-020.2404image
chr3:197884170-197886782:+OVEERT_cells_CD82.7726e-040.2123image
ENSG00000186001.11,LRCH3OVEAGT_cells_CD81.0486e-030.1918image
chr3:197884170-197886782:+PAADEERNK_cells_resting3.5321e-030.2182image
ENSG00000186001.11,LRCH3PAADEAGNK_cells_resting2.0132e-030.2306image
chr3:197884170-197886782:+PRADEERPlasma_cells3.6576e-02-0.0939image
ENSG00000186001.11,LRCH3PRADEAGPlasma_cells1.6378e-02-0.1076image
chr3:197884170-197886782:+READEERDendritic_cells_resting4.0128e-030.2957image
ENSG00000186001.11,LRCH3READEAGDendritic_cells_resting6.7781e-030.2789image
ENSG00000186001.11,LRCH3SARCEAGB_cells_naive4.8510e-02-0.1234image
chr3:197884170-197886782:+SKCMEERT_cells_CD84.9965e-020.0904image
chr3:197844710-197845339:+STADEERMast_cells_activated5.5962e-030.2568image
chr3:197872187-197875463:+STADEERMacrophages_M02.7758e-020.1803image
chr3:197884170-197886782:+STADEERT_cells_CD4_memory_activated1.9077e-050.2215image
ENSG00000186001.11,LRCH3STADEAGT_cells_CD4_memory_activated6.8123e-040.1763image
chr3:197884170-197886782:+TGCTEERT_cells_regulatory_(Tregs)2.8476e-03-0.2374image
ENSG00000186001.11,LRCH3TGCTEAGT_cells_regulatory_(Tregs)2.5786e-03-0.2397image
chr3:197884170-197886782:+THYMEERMast_cells_resting7.8658e-030.2436image
ENSG00000186001.11,LRCH3THYMEAGMast_cells_resting1.1151e-020.2329image
chr3:197884170-197886782:+UCECEERDendritic_cells_resting1.9252e-02-0.1763image
ENSG00000186001.11,LRCH3UCECEAGMast_cells_activated2.2663e-02-0.1717image
chr3:197884170-197886782:+UCSEERMast_cells_activated4.6384e-020.2673image
chr3:197884170-197886782:+UVMEERNK_cells_activated2.0483e-02-0.2637image
ENSG00000186001.11,LRCH3UVMEAGNK_cells_activated1.6918e-02-0.2715image


Top

6. Enriched editing regions and immune gene sets for LRCH3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr3:197884170-197886782:+BLCAEER1.0112e-02image2.3970e-020.1126image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr3:197884170-197886782:+BLCAEER5.3421e-030.13871.3851e-040.18899.6765e-030.12898.1075e-030.1319image
ENSG00000186001.11,LRCH3BLCAEAG7.3731e-030.13351.3612e-040.18921.0951e-020.12682.6615e-020.1106image
chr3:197884170-197886782:+BRCAEER1.4526e-120.21361.3008e-070.16012.6356e-080.16863.9765e-020.0627image
chr3:197884170-197886782:+LUADEER2.3271e-030.13852.0305e-020.10581.8896e-020.10705.0510e-040.1580image
chr3:197884170-197886782:+SARCEER3.0682e-030.18441.5041e-020.15183.8094e-020.12974.2863e-050.2528image
ENSG00000186001.11,LRCH3SARCEAG4.6671e-030.17632.6402e-020.13884.0032e-020.12845.1709e-050.2502image
chr3:197884170-197886782:+STADEER2.8190e-080.28526.3801e-030.14232.3340e-050.21921.2424e-030.1682image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr3:197884170-197886782:+ACCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.8369e-020.2773image
ENSG00000186001.11,LRCH3ACCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.2739e-02-0.2502image
chr3:197884170-197886782:+BLCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.0332e-050.2064image
ENSG00000186001.11,LRCH3BLCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG7.5475e-050.1961image
ENSG00000186001.11,LRCH3BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.2661e-090.1832image
chr3:197884170-197886782:+BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER2.8215e-130.2201image
ENSG00000186001.11,LRCH3CESCGSVA_HALLMARK_ADIPOGENESISEAG6.6550e-040.1951image
chr3:197884170-197886782:+CESCGSVA_HALLMARK_ADIPOGENESISEER2.7743e-040.2081image
chr3:197884170-197886782:+COADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER7.0245e-050.2463image
ENSG00000186001.11,LRCH3COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.7362e-06-0.2734image
chr3:197884170-197886782:+DLBCGSVA_HALLMARK_MTORC1_SIGNALINGEER1.8558e-030.4379image
ENSG00000186001.11,LRCH3DLBCGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.0266e-030.4346image
chr3:197884170-197886782:+ESCAGSVA_HALLMARK_GLYCOLYSISEER8.2925e-030.2074image
chr3:197863386-197865289:+ESCAGSVA_HALLMARK_COAGULATIONEER2.3152e-020.3207image
ENSG00000186001.11,LRCH3ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.9311e-03-0.2120image
chr3:197872187-197875463:+ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6100e-040.3651image
ENSG00000186001.11,LRCH3GBMGSVA_HALLMARK_DNA_REPAIREAG5.3724e-030.2184image
chr3:197884170-197886782:+GBMGSVA_HALLMARK_DNA_REPAIREER6.0437e-030.2155image
chr3:197884170-197886782:+HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.6054e-050.1880image
ENSG00000186001.11,LRCH3HNSCGSVA_HALLMARK_HYPOXIAEAG8.8447e-050.1755image
ENSG00000186001.11,LRCH3KIRCGSVA_HALLMARK_ANGIOGENESISEAG2.0053e-04-0.1904image
chr3:197884170-197886782:+KIRCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER9.2487e-050.2002image
chr3:197884170-197886782:+KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.3670e-050.2377image
ENSG00000186001.11,LRCH3KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.2672e-050.2490image
chr3:197863386-197865289:+LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.7320e-02-0.2009image
chr3:197872187-197875463:+LAMLGSVA_HALLMARK_MYC_TARGETS_V2EER4.5755e-020.2330image
ENSG00000186001.11,LRCH3LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0552e-08-0.2460image
chr3:197884170-197886782:+LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.1522e-08-0.2383image
ENSG00000186001.11,LRCH3LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1401e-09-0.3177image
chr3:197884170-197886782:+LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.9457e-080.2914image
ENSG00000186001.11,LRCH3LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG7.5578e-050.1787image
chr3:197884170-197886782:+LUADGSVA_HALLMARK_GLYCOLYSISEER3.0563e-060.2110image
chr3:197884170-197886782:+LUSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.7670e-090.2610image
ENSG00000186001.11,LRCH3LUSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.5057e-080.2510image
ENSG00000186001.11,LRCH3MESOGSVA_HALLMARK_COAGULATIONEAG6.1888e-030.2999image
chr3:197884170-197886782:+MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER8.9527e-030.2870image
ENSG00000186001.11,LRCH3OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.6940e-070.2970image
chr3:197884170-197886782:+OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.0912e-080.3185image
chr3:197884170-197886782:+PAADGSVA_HALLMARK_GLYCOLYSISEER5.3110e-030.2087image
ENSG00000186001.11,LRCH3PAADGSVA_HALLMARK_GLYCOLYSISEAG5.2356e-030.2090image
chr3:197884170-197886782:+PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.6642e-03-0.2360image
ENSG00000186001.11,LRCH3PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.5488e-03-0.2268image
ENSG00000186001.11,LRCH3PRADGSVA_HALLMARK_E2F_TARGETSEAG1.2148e-030.1447image
chr3:197884170-197886782:+PRADGSVA_HALLMARK_MYC_TARGETS_V1EER3.6035e-040.1596image
ENSG00000186001.11,LRCH3READGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.4863e-040.3834image
chr3:197884170-197886782:+READGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER8.1514e-040.3413image
ENSG00000186001.11,LRCH3SARCGSVA_HALLMARK_HYPOXIAEAG5.1709e-050.2502image
chr3:197884170-197886782:+SARCGSVA_HALLMARK_HYPOXIAEER4.2863e-050.2528image
chr3:197884170-197886782:+SKCMGSVA_HALLMARK_UV_RESPONSE_DNEER1.3022e-07-0.2403image
ENSG00000186001.11,LRCH3SKCMGSVA_HALLMARK_UV_RESPONSE_DNEAG9.1004e-08-0.2432image
chr3:197872187-197875463:+STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.1327e-030.2405image
chr3:197844710-197845339:+STADGSVA_HALLMARK_ANGIOGENESISEER1.6364e-040.3444image
chr3:197841887-197843040:+STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.3587e-020.3535image
chr3:197884170-197886782:+STADGSVA_HALLMARK_MTORC1_SIGNALINGEER1.4585e-090.3094image
ENSG00000186001.11,LRCH3STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.0411e-030.1703image
ENSG00000186001.11,LRCH3TGCTGSVA_HALLMARK_GLYCOLYSISEAG2.3615e-040.2904image
chr3:197884170-197886782:+TGCTGSVA_HALLMARK_GLYCOLYSISEER1.0269e-030.2604image
ENSG00000186001.11,LRCH3THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG5.5615e-03-0.1237image
chr3:197884170-197886782:+THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER5.0800e-03-0.1250image
ENSG00000186001.11,LRCH3THYMGSVA_HALLMARK_SPERMATOGENESISEAG2.7208e-02-0.2034image
chr3:197884170-197886782:+THYMGSVA_HALLMARK_SPERMATOGENESISEER3.4692e-02-0.1946image
chr3:197884170-197886782:+UCECGSVA_HALLMARK_HEME_METABOLISMEER1.2247e-020.1885image
ENSG00000186001.11,LRCH3UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.2372e-020.1721image
ENSG00000186001.11,LRCH3UCSGSVA_HALLMARK_MYC_TARGETS_V2EAG5.1036e-030.3692image
chr3:197884170-197886782:+UCSGSVA_HALLMARK_MTORC1_SIGNALINGEER3.2419e-030.3867image


Top

7. Enriched editing regions and drugs for LRCH3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000186001.11,LRCH3ACCJNJ.26854165EAG3.4814e-02-0.2474image
chr3:197884170-197886782:+ACCJNJ.26854165EER1.1853e-02-0.2951image
chr3:197884170-197886782:+BLCAJNK.Inhibitor.VIIIEER3.8676e-04-0.1762image
ENSG00000186001.11,LRCH3BLCAAICAREAG6.7121e-04-0.1689image
ENSG00000186001.11,LRCH3BRCACHIR.99021EAG2.6924e-050.1272image
chr3:197884170-197886782:+BRCACCT007093EER1.7463e-060.1451image
ENSG00000186001.11,LRCH3CESCCHIR.99021EAG8.4045e-030.1516image
chr3:197884170-197886782:+CESCCHIR.99021EER5.6419e-030.1592image
chr3:197884170-197886782:+CHOLEtoposideEER1.9404e-020.3934image
ENSG00000186001.11,LRCH3CHOLAMG.706EAG2.3945e-020.3810image
chr3:197884170-197886782:+COADCCT007093EER1.6302e-040.2340image
ENSG00000186001.11,LRCH3COADBMS.708163EAG7.6308e-06-0.2735image
chr3:197884170-197886782:+DLBCLapatinibEER1.3329e-030.4500image
ENSG00000186001.11,LRCH3DLBCLapatinibEAG1.1005e-030.4568image
chr3:197872187-197875463:+ESCAImatinibEER9.2727e-03-0.2565image
chr3:197884170-197886782:+ESCACCT018159EER4.8262e-03-0.2218image
chr3:197863386-197865289:+ESCAAZD.0530EER9.7317e-03-0.3623image
ENSG00000186001.11,LRCH3ESCACGP.60474EAG1.3813e-03-0.2500image
chr3:197844710-197845339:+ESCAAZD7762EER3.6540e-03-0.3478image
chr3:197884170-197886782:+GBMBMS.509744EER8.2779e-04-0.2609image
ENSG00000186001.11,LRCH3GBMBMS.509744EAG8.7276e-04-0.2598image
ENSG00000186001.11,LRCH3HNSCBMS.708163EAG7.0466e-05-0.1778image
chr3:197884170-197886782:+HNSCBMS.708163EER5.2502e-05-0.1809image
ENSG00000186001.11,LRCH3KICHEmbelinEAG4.8917e-030.3476image
ENSG00000186001.11,LRCH3KIRCAP.24534EAG2.3721e-060.2403image
chr3:197884170-197886782:+KIRCAZD6482EER2.0717e-060.2429image
ENSG00000186001.11,LRCH3KIRPIPA.3EAG1.5305e-040.2232image
chr3:197884170-197886782:+KIRPIPA.3EER2.9371e-040.2137image
ENSG00000186001.11,LRCH3LAMLABT.263EAG2.2295e-02-0.1917image
chr3:197884170-197886782:+LAMLAS601245EER3.5802e-030.2845image
chr3:197863386-197865289:+LAMLGDC.0449EER4.9295e-030.2818image
ENSG00000186001.11,LRCH3LGGCyclopamineEAG6.4537e-080.2328image
chr3:197884170-197886782:+LGGCyclopamineEER5.0371e-080.2349image
chr3:197884170-197886782:+LIHCDoxorubicinEER7.9506e-100.3214image
ENSG00000186001.11,LRCH3LIHCDoxorubicinEAG8.7365e-120.3538image
chr3:197884170-197886782:+LUADErlotinibEER1.3171e-03-0.1461image
ENSG00000186001.11,LRCH3LUADGemcitabineEAG6.0547e-04-0.1552image
chr3:197872187-197875463:+LUSCABT.888EER2.8030e-02-0.4578image
ENSG00000186001.11,LRCH3LUSCCCT007093EAG2.2288e-090.2646image
chr3:197884170-197886782:+LUSCCCT007093EER1.4533e-090.2676image
chr3:197884170-197886782:+MESOBIRB.0796EER2.7466e-030.3266image
ENSG00000186001.11,LRCH3MESOBIRB.0796EAG1.8960e-030.3380image
chr3:197872187-197875463:+OVErlotinibEER2.0968e-02-0.2578image
ENSG00000186001.11,LRCH3OVCCT007093EAG3.9644e-070.2930image
chr3:197884170-197886782:+OVCCT007093EER4.1253e-070.2925image
chr3:197884170-197886782:+PAADCCT007093EER2.0211e-030.2305image
ENSG00000186001.11,LRCH3PAADCCT007093EAG2.0942e-030.2298image
ENSG00000186001.11,LRCH3PCPGAS601245EAG1.9395e-040.2781image
chr3:197884170-197886782:+PCPGAS601245EER1.3143e-040.2851image
ENSG00000186001.11,LRCH3PRADCCT018159EAG1.4556e-040.1696image
chr3:197884170-197886782:+PRADJNK.9LEER1.4733e-040.1696image
chr3:197884170-197886782:+READMG.132EER1.3841e-04-0.3850image
ENSG00000186001.11,LRCH3READLenalidomideEAG1.2340e-030.3300image
chr3:197884170-197886782:+SARCAMG.706EER1.4422e-03-0.1981image
ENSG00000186001.11,LRCH3SARCAMG.706EAG1.2797e-03-0.2002image
chr3:197884170-197886782:+SKCMEmbelinEER6.3544e-050.1832image
ENSG00000186001.11,LRCH3SKCMEmbelinEAG3.3756e-050.1898image
ENSG00000186001.11,LRCH3STADAxitinibEAG1.9829e-030.1612image
chr3:197872187-197875463:+STADMidostaurinEER1.7933e-03-0.2537image
chr3:197863386-197865289:+STADKU.55933EER3.1498e-020.2520image
chr3:197841887-197843040:+STADBMS.708163EER6.2835e-03-0.4659image
chr3:197844710-197845339:+STADAZD.0530EER1.2009e-02-0.2388image
chr3:197884170-197886782:+STADCCT007093EER1.5060e-040.1968image
ENSG00000186001.11,LRCH3TGCTEHT.1864EAG9.2800e-050.3078image
chr3:197884170-197886782:+TGCTGW.441756EER6.3888e-04-0.2704image
chr3:197884170-197886782:+THCAIPA.3EER7.0425e-060.1992image
ENSG00000186001.11,LRCH3THCAIPA.3EAG2.5154e-050.1870image
chr3:197884170-197886782:+THYMKIN001.135EER3.5336e-02-0.1939image
ENSG00000186001.11,LRCH3THYMBAY.61.3606EAG1.8819e-020.2160image
chr3:197884170-197886782:+UCECBMS.708163EER1.7180e-02-0.1794image
ENSG00000186001.11,LRCH3UCECBMS.708163EAG8.3046e-03-0.1984image
ENSG00000186001.11,LRCH3UCSGDC.0449EAG3.2018e-02-0.2870image
chr3:197884170-197886782:+UCSCCT007093EER2.0063e-020.3100image
chr3:197884170-197886782:+UVMMetforminEER3.5127e-02-0.2405image
ENSG00000186001.11,LRCH3UVMMetforminEAG4.0280e-02-0.2343image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType